BIO International Convention Begins Day Three with Jamie Dimon Keynote Address

Wednesday programming will feature timely discussions on diversity,
inclusion and R&D investment

PHILADELPHIA–(BUSINESS WIRE)–The 2019
BIO International Convention, the premier life sciences event
running through June 6 at the Philadelphia Convention Center, will open
its third day of programming with a keynote from Jamie Dimon, Chairman
and CEO of JPMorgan Chase. Dimon will be interviewed by BIO President
and CEO Jim Greenwood on how emerging biotech companies can best
position themselves in the global economy. Dimon will also share insight
on how the industry can improve employee satisfaction and cultivate a
diverse and inclusive biotech community.

The day’s programming will also include compelling sessions with
industry thought leaders, rising start-up companies as well as a
fireside chat with Merck Chairman and CEO Ken Frazier. During his
fireside chat, Frazier will discuss how Merck approaches investment in
research and how that translates to delivering innovative, lifesaving
medicines and vaccines and sustainable value for its stakeholders.

Wednesday, June 5, Highlights Include:

• Keynote: Jamie
  Dimon, Chairman and CEO of JPMorgan Chase
  9:00 – 10:45
  am | Ballroom AB
  • PLEASE NOTE: Keynotes are open to Convention Access and
    Partnering Attendees. Filming is not permitted. Seating is
    first-come, first-served.
• Fireside Chat: Kenneth
  C. Frazier, Chairman of the Board and Chief Executive Officer, Merck &
  Co., Inc.
  11:00 – 11:45 am | 103ABC, Level 100
  During
  his fireside chat, Kenneth Frazier will discuss how Merck is
  delivering innovative, lifesaving medicines and vaccines as well as
  long-term and sustainable value to its stakeholders.
• Super Session: Dealmakers’
  Intentions: 2019 Market Outlook
  12:15 – 1:30 pm |
  113ABC, Level 100
  A panel of deal-makers will explore the
  impact market forces will have on pharmaceutical and biotech companies
  as they strive to make the next big deal.

• Super Session: The
  Art & Science of R&D Innovation and Productivity
  12:15
  – 1:30 pm | 103ABC, Level 100
  A panel will seek to
  understand how companies of various sizes think about R&D innovation
  and productivity today, from operating and business models to
  measurement.

• Super Session: The
  State of the Vaccine Industry – Stimulating Sustainable Growth
  3:00
  – 4:15 pm | 113ABC, Level 100
  This session will focus on
  the various ways vaccine companies and partners can stimulate
  continued growth of the vaccine business by fostering innovation with
  new target vaccines, new technology and solutions to access issues
  that will increase immunization rates.

• Start-Up
  Stadium
  10:30 am – 1:00 pm | Exhibitor Hall, 3971,
  Level 200
  Designed to provide start-up-level companies
  with the opportunity to engage key members of the investment community
  and venture philanthropy groups. BIO attendees can watch these
  impressive companies pitch their products to a panel of investor
  judges.

Follow the 2019 Convention @BIOConvention
and join the conversation @IAmBIOtech.

About BIO

BIO is the world’s largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention, the world’s largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW is
BIO’s blog chronicling “innovations transforming our world” and the BIO
Newsletter is the organization’s bi-weekly email newsletter. Subscribe
to the BIO Newsletter.

Contacts

Biotechnology Innovation Organization (BIO)
Theresa Brady
202-962-9235
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech